Anthony G. Viscogliosi has twenty-three years
of experience as an accomplished founder, entrepreneur, CEO, board
member, leading Wall Street analyst, author, visionary and lecturer.
He was the first Wall Street orthopedic industry analyst and has
authored more than 6,000 pages of investment research on orthopedics.
He was also the first Wall Street Orthopedic Investment Banker and
has executed more than 170 orthopedic deals of every type as principal
or agent, buyer and seller.
Mr. Viscogliosi is a founder of Small Bone Innovations, Inc., where
he currently serves as Chairman and Chief Executive Officer. He
raised $42.2 million for Small Bone Innovations, Inc. – the
single largest round of venture capital financing in orthopedic
history at that time. Small Bone Innovations, Inc. was recognized
by Red Herring Magazine as one of the Top 100 Companies in North
America – the only orthopedic company in the Top 100. Mr.
Viscogliosi co-founded Viscogliosi Bros., LLC, the leading merchant
bank and venture capital firm focused on the musculoskeletal/orthopedics
industry, in 1999. Mr. Viscogliosi is a founder of the leading multi
product spine non-fusion private company, Paradigm Spine, LLC. Mr.
Viscogliosi is also a founder of the leading Spine Arthroplasty
company, Spine Solutions, Inc.; financial founder of the leading
Nucleus Arthroplasty company RayMedica, Inc.; founder of the leading
reprocessor of single use disposable devices in the USA, Ascent
Healthcare Solutions, Inc.; board member of SpineNext in its sale
to Abbott; co-founder of a full service Brokerage Firm and Investment
Bank, Viscogliosi & Company, Inc.; a co-founder of the leading
orthopedic clinical, regulatory, IP and Reimbursement Consulting
firm, Musculoskeletal Clinical & Regulatory Advisers, LLC; a
founder and Partner in 6 orthopedic focused venture capital &
private equity funds, as well as the only orthopedic focused hedge
fund. In addition, he is a founder of the NYU-HJD Viscogliosi Bros.
Mr. Viscogliosi received his B.S. in Economics from the University
of Michigan in 1984. Prior to co-founding Viscogliosi Bros., he
served with several regional brokerage and investment banking firms,
as a Senior Vice President and Director of Medical Technology, Co-Director
of Research, Assistant Director of Research and as an Equity Research
Mr. Viscogliosi was direct-commissioned as an officer in the U.S.
Navy Reserve in 1990 during Operation Desert Shield, and is currently
a Lieutenant Commander of the United States Navy Reserve. He served
on-board the aircraft carrier USS Theodore Roosevelt CVN-71 during
the NATO/Bosnia war in 1995, and has served in the Middle East,
including Jordan and Bahrain. He was also in Korea during the beginning
of the Iraq war, and served as Assistant Officer-In-Charge and Supply
Corp Officer for the U.S. Navy Ceremonial Guard which serves the
President, Vice President, Joint Chiefs of Staff and Secretary of
Mr. Viscogliosi is involved in numerous academic, charitable and
philanthropic activities as well. He formerly served as a board
member for the Hospital for Joint Diseases and is currently a member
of the New York University-HJD Advisory Board. He also serves on
the Editorial Council for MX Magazine; Vice-Chairman on the Board
of Directors for Junior Achievement of New York; Co-Chairman of
the Junior Achievement Endowment Campaign; Co-Chairman of The Chancellor’s
Campaign Council at the University of Michigan – Dearborn;
Member of The University of Michigan Tri-State Gifts Committee and
Henry Ford Estate Advisory Board; Founder and Sponsor of The University
of Michigan – Dearborn Viscogliosi Leadership Seminar Series,
and is a member of The Woodrow Wilson Council.
A talented, driven and experienced strategist
and tactician in investing, building and leading musculoskeletal
companies with interim CFO, intellectual property managment, ISO
9001 and CE Mark experience. Prior to co-founding Viscogliosi Brothers,
LLC in 1999, Mr. Viscogliosi was employed for seven years by several
regional brokerage and investment banking firms. Mr. Viscogliosi
has broad capital markets experience in institutional and retail
sales, institutional listed trading, back office functions and money
management. Mr. Viscogliosi has been a Vice President of Investments
at Stifel, Nicolaus & Co., Inc., an Associate Director of Investments
at Rodman & Renshaw, an Account Executive at First of Michigan
Corp. and Dean Witter Reynolds, Inc. and an assistant in the institutional
sales and trading department of Martin Simpson & Co., Inc. Mr.
Viscogliosi has served on the Board of Directors of three musculoskeletal
companies. Mr. Viscogliosi graduated from Wayne State University
with a BS in Criminal Justice in 1992.
A well seasoned leader, manager and clinical
and regulatory strategic thinker with six years of investment research,
banking and operational experience in musculoskeletal new business
development. Prior to co-founding Viscogliosi Brothers, LLC in 1999,
Mr. Viscogliosi had spent six years researching and banking musculoskeletal
companies. He was employed for four years as a musculoskeletal/orthopedic
research associate, primarily working with his brother, Anthony.
Mr. Viscogliosi was a research associate at Stifel, Nicolaus &
Co., Inc., Rodman & Renshaw, Inc. and Commonwealth Associates.
From 1992 to 1993 Mr. Viscogliosi worked as an intern at Martin
Simpson & Co. Mr. Viscogliosi has served on two Boards of Directors
of musculoskeletal companies. Mr. Viscogliosi graduated from New
York University in 1999 with a BA in Economics and Political Science.
General Manager, MCRA
Mr. David W. Lown has more than 8 years of experience
specific to the orthopedic industry and currently serves as General
Manager for Musculoskeletal Clinical and Regulatory Advisers,
LLC (MCRA). Mr. Lown is responsible for the operational execution
and growth of MCRA’s 5 service areas (regulatory, clinical,
reimbursement, intellectual property, and quality assurance).
Mr. Lown joined the firm in August 2006.
Prior to joining MCRA, Mr. Lown has been employed at Viscogliosi
Brothers, LLC (VB), the first and premier merchant banking firm
focused on the orthopedic industry. Mr. Lown has worked both for
VB’s merchant banking initiatives and as an operating employee
within 3 of its portfolio companies. For VB’s merchant banking
initiatives, Mr. Lown has worked on the company’s 6 venture
funds performing portfolio company investment due diligence, financial
and fund analysis, and both US and international deal structuring
and transaction execution. Furthermore, Mr. Lown has been responsible
in the creation of VB’s 5 most recent company creations:
Spine Solutions, Inc. (1999), Paradigm Spine, LLC (2004), Small
Bone Innovations, Inc. (2004), and Musculoskeletal Clinical and
Regulatory Advisers, LLC (2004) and Surgisoft, LLC (2006). Lastly,
Mr. Lown has been responsible for oversight of VB’s principal
investments, including Spine Next, SA and Raymedica, Inc.
From an operational standpoint, Mr. Lown’s most recent position
has been as Director, Corporate Finance for Small Bone Innovations
when he joined the company in August 2004. Mr. Lown was responsible
for identifying and structuring mergers and acquisitions, licensing
and other corporate-partnering activities, and as such assisted
the CEO in the completion of 17 transactions in a two year period.
Additionally, Mr. Lown managed a team of upwards of 7 analysts
responsible for the company’s financial projections, M&A
due diligence, intellectual property, internal analytics, and
industry research/competitive intelligence. Mr. Lown also served
as a Financial Analyst for Spine Solutions, Inc., the developer
of the ProDisc® Lumbar & Cervical total disc technologies
that were sold to Synthes, Inc. for $350 million in April 2003.
Mr. Lown graduated from Fordham University with a Bachelor of
Science degree in Finance..
C. Dunne, CFA
Mr. Dunne joined VB in December 2003 as the portfolio
manager for Orthopedic Investment Partners, LP, a musculoskeletal-focused
hedge fund launched by VB in January 2004. Mr. Dunne brings more
than 30 years of Wall Street medical-device specific investing
experience as a leading analyst and hedge fund portfolio manager
with Martin Simpson & Company and as an analyst with Wasserstein,